Medicure (TSE:MPH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Medicure Inc. reported a decrease in total net revenue to $5.2 million in Q2 of 2024, down from $6.0 million in the same quarter the previous year, with significant drops in sales from its AGGRASTAT product due to increased generic competition. The company also experienced a net loss of $1.2 million, a stark contrast to the net income of $253,000 reported in Q2 of 2023.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.